Repositorio
Institucional

Roa, Juan Carlos

Perez-Moreno, Pablo

Riquelme, Ismael

Garcia, Patricia

Brebi, Priscilla

Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer

MDPI

JOURNAL OF PERSONALIZED MEDICINE

en

Gallbladder cancer (GBC) is an aggressive neoplasm that in an early stage is generally asymptomatic and, in most cases, is diagnosed in advanced stages with a very low life expectancy because there is no curative treatment. Therefore, understanding the early carcinogenic mechanisms of this pathology is crucial to proposing preventive strategies for this cancer. The main risk factor is the presence of gallstones, which are associated with some environmental factors such as a sedentary lifestyle and a high-fat diet. Other risk factors such as autoimmune disorders and bacterial, parasitic and fungal infections have also been described. All these factors can generate a long-term inflammatory state characterized by the persistent activation of the immune system, the frequent release of pro-inflammatory cytokines, and the constant production of reactive oxygen species that result in a chronic damage/repair cycle, subsequently inducing the loss of the normal architecture of the gallbladder mucosa that leads to the development of GBC. This review addresses how the different risk factors could promote a chronic inflammatory state essential to the development of gallbladder carcinogenesis, which will make it possible to define some strategies such as anti-inflammatory drugs or public health proposals in the prevention of GBC.

artículo original

This research received funding from the National Fund for Scientific and Technological Development (FONDECYT) [No. 3210237 to P.P.-M., No. 1210440 to P.B., No. 1221345 to J.C.R.], the Research Direction from Universidad Autonoma de Chile (DIUA) [No. 226-2021 to I.R.], the Re-search Direction from Universidad de La Frontera (DIUFRO) [No. DI20-0128 to P.B.], FONDEF Idea [No. ID21I10027 to P.B.], the Millennium Institute on Immunology and Immunotherapy (IMII) [No. ICN2021_045 to P.P.-M., P.G., J.C.R. and P.B.], and the European Research Council (ERC) under the European Unions Horizon 2020 Research and Innovation Programme [No. 825510 to J.C.R.].

Esta investigación recibió financiamiento del Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) [No. 3210237 a P.P.-M., No. 1210440 a P.B., N° 1221345 a J.C.R.], la Dirección de Investigaciones de la Universidad Autónoma de Chile (DIUA) [N°. 226-2021 a I.R.], la Dirección de Investigación de la Universidad de La Frontera (DIUFRO) [N°. DI20-0128 a P.B.], Idea FONDEF [No. ID21I10027 a P.B.], el Instituto Milenio de Inmunología e Inmunoterapia (IMII) [No. ICN2021_045 a P.P.-M., P.G., J.C.R. y P.B.], y el Consejo Europeo de Investigación (ERC) en el marco del Programa de Investigación e Innovación Horizonte 2020 de la Unión Europea [No. 825510 a J.C.R.].

This research received funding from the National Fund for Scientific and Technological Development (FONDECYT) [No. 3210237 to P.P.-M.; No. 1210440 to P.B.; No. 1221345 to J.C.R.], the Research Direction from Universidad Autonoma de Chile (DIUA) [No. 226-2021 to I.R.], the Re-search Direction from Universidad de La Frontera (DIUFRO) [No. DI20-0128 to P.B.], FONDEF Idea [No. ID21I10027 to P.B.], the Millennium Institute on Immunology and Immunotherapy (IMII) [No. ICN2021_045 to P.P.-M., P.G., J.C.R. and P.B.], and the European Research Council (ERC) under the European Unions Horizon 2020 Research and Innovation Programme [No. 825510 to J.C.R.].

Esta investigación recibió financiamiento del Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) [No. 3210237 a P.P.-M.; No. 1210440 a P.B.; N° 1221345 a J.C.R.], la Dirección de Investigaciones de la Universidad Autónoma de Chile (DIUA) [N°. 226-2021 a I.R.], la Dirección de Investigación de la Universidad de La Frontera (DIUFRO) [N°. DI20-0128 a P.B.], Idea FONDEF [No. ID21I10027 a P.B.], el Instituto Milenio de Inmunología e Inmunoterapia (IMII) [No. ICN2021_045 a P.P.-M., P.G., J.C.R. y P.B.], y el Consejo Europeo de Investigación (ERC) en el marco del Programa de Investigación e Innovación Horizonte 2020 de la Unión Europea [No. 825510 a J.C.R.].

10.3390/jpm12020234

PDF

gallbladder cancer

risk factors

carcinogenesis

PRIMARY SCLEROSING CHOLANGITIS

BILIARY-TRACT CANCER

HEPATITIS-B-VIRUS

BODY-MASS INDEX

ANOMALOUS ARRANGEMENT

PRENEOPLASTIC LESIONS

ALCOHOL-CONSUMPTION

HELICOBACTER-BILIS

GENE POLYMORPHISMS

SIGNALING PATHWAYS

Ciencias y Servicios de Atención Médica

Medicina general e interna

cáncer de vesícula biliar

factores de riesgo

carcinogénesis

COLANGITIS ESCLEROSANTE PRIMARIA

CÁNCER DE VÍAS BILIAR

HEPATITIS-B-VIRUS

ÍNDICE DE MASA CORPORAL

DISPOSICIÓN ANÓMALA

LESIONES PRENEOPLÁSICAS

CONSUMO DE ALCOHOL

HELICOBACTER-BILIS

POLOMORFISMOS GENÉTICOS

VÍAS DE SEÑALIZACIÓN

Oncología

Gastroenterología y Hepatología

Patología

Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer

artículo original

version publicada

CC BY 4.0

CC BY 4.0

acceso abierto

acceso abierto

ANID-FONDECYT 3210237

ANID-FONDECYT 1210440

ANID-FONDECYT 1221345

UA 226-2021

UCT FIAII 2021-01

ANID-FONDEF 21I10027

IMII ICN2021_045

UE 825510

ANID FONDECYT 3210237

ANID FONDECYT 1210440

ANID FONDECYT 1221345

ANID FONDEF 21I10027

WOS:000763731500001